Robert F. Gagel

25.9k total citations · 5 hit papers
221 papers, 14.7k citations indexed

About

Robert F. Gagel is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology. According to data from OpenAlex, Robert F. Gagel has authored 221 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Endocrinology, Diabetes and Metabolism, 81 papers in Oncology and 60 papers in Molecular Biology. Recurrent topics in Robert F. Gagel's work include Thyroid Cancer Diagnosis and Treatment (61 papers), Neuroendocrine Tumor Research Advances (44 papers) and Bone health and treatments (31 papers). Robert F. Gagel is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (61 papers), Neuroendocrine Tumor Research Advances (44 papers) and Bone health and treatments (31 papers). Robert F. Gagel collaborates with scholars based in United States, Germany and United Kingdom. Robert F. Gagel's co-authors include Gilbert J. Cote, Douglas B. Evans, Samuel A. Wells, Martin Schlumberger, Jeffrey F. Moley, Jeffrey E. Lee, Ana O. Hoff, Henning Dralle, Rossella Elisei and Furio Pacini and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Robert F. Gagel

218 papers receiving 14.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

2015 1.4k citations Samuel A. Wells, L. Sylvia et al. Thyroid profile →
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

2011 1.1k citations Samuel A. Wells, Bruce G. Robinson et al. Journal of Clinical Oncology profile →
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

2009 853 citations Douglas B. Evans, Robert F. Gagel et al. Thyroid profile →
Mutations in the Sulfonylurea Receptor Gene in Familial Persistent Hyperinsulinemic Hypoglycemia of Infancy

1995 632 citations Pamela M. Thomas, Gilbert J. Cote et al. profile →
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

2011 445 citations Steven I. Sherman, David G. Pfister et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert F. Gagel United States	58	7.1k	4.7k	3.9k	3.6k	3.2k	221	14.7k
Samuel A. Wells United States	62	8.1k 1.1×	4.7k 1.0×	3.9k 1.0×	3.7k 1.0×	4.1k 1.3×	256	16.2k
Shereen Ezzat Canada	67	11.1k 1.6×	2.5k 0.5×	4.4k 1.1×	4.2k 1.2×	3.1k 1.0×	317	16.4k
Orlo H. Clark United States	71	9.6k 1.3×	3.7k 0.8×	7.2k 1.8×	3.0k 0.8×	2.1k 0.6×	347	17.1k
Mauro Papotti Italy	66	5.7k 0.8×	5.8k 1.3×	4.0k 1.0×	2.5k 0.7×	5.5k 1.7×	382	17.1k
Bruce G. Robinson Australia	56	5.0k 0.7×	2.2k 0.5×	3.0k 0.8×	3.4k 0.9×	1.6k 0.5×	227	11.3k
Bruno Niederle Austria	56	4.3k 0.6×	4.1k 0.9×	4.1k 1.1×	1.4k 0.4×	4.3k 1.3×	327	11.6k
Catharina Larsson Sweden	62	3.1k 0.4×	4.2k 0.9×	2.1k 0.5×	6.1k 1.7×	3.1k 1.0×	358	14.4k
Barbara Jarząb Poland	49	6.5k 0.9×	2.6k 0.6×	1.8k 0.4×	3.4k 1.0×	1.4k 0.4×	270	11.3k
Henning Dralle Germany	73	15.9k 2.2×	4.7k 1.0×	13.8k 3.5×	4.0k 1.1×	6.1k 1.9×	585	26.8k
Göran Åkerström Sweden	56	2.0k 0.3×	4.2k 0.9×	2.6k 0.7×	2.2k 0.6×	3.7k 1.1×	293	11.5k

Countries citing papers authored by Robert F. Gagel

Since Specialization

Citations

This map shows the geographic impact of Robert F. Gagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert F. Gagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert F. Gagel more than expected).

Fields of papers citing papers by Robert F. Gagel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert F. Gagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert F. Gagel. The network helps show where Robert F. Gagel may publish in the future.

Co-authorship network of co-authors of Robert F. Gagel

This figure shows the co-authorship network connecting the top 25 collaborators of Robert F. Gagel. A scholar is included among the top collaborators of Robert F. Gagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert F. Gagel. Robert F. Gagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Huan, Jin He, Rozita Bagheri‐Yarmand, et al.. (2022). Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nature Communications. 13(1). 3684–3684. 17 indexed citations

Bethel, M. Angelyn, Rishi Patel, Vivian P. Thompson, et al.. (2019). Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care. 42(6). 1075–1080. 26 indexed citations

Bagheri‐Yarmand, Rozita, Krishna M. Sinha, Ling Li, et al.. (2018). Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress–Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Molecular Cancer Research. 17(3). 751–760. 26 indexed citations

Wallace, Taylor C., Douglas C. Bauer, Robert F. Gagel, et al.. (2016). The National Osteoporosis Foundation’s methods and processes for developing position statements. Archives of Osteoporosis. 11(1). 22–22. 6 indexed citations

Xu, Jian, William A. Murphy, Denái R. Milton, et al.. (2016). Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 101(12). 4871–4877. 22 indexed citations

Wells, Samuel A., L. Sylvia, Henning Dralle, et al.. (2015). Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 25(6). 567–610. 1443 indexed citations breakdown →

Tuvim, Michael J., Cecilia Clement, Gilbert J. Cote, et al.. (2013). Deletion of the Gene Encoding Calcitonin and Calcitonin Gene–Related Peptide α Does Not Affect the Outcome of Severe Infection in Mice. American Journal of Respiratory Cell and Molecular Biology. 49(1). 151–155. 4 indexed citations

Wells, Samuel A., Bruce G. Robinson, Robert F. Gagel, et al.. (2011). Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 30(2). 134–141. 1082 indexed citations breakdown →

Wells, Samuel A., Jessica E. Gosnell, Robert F. Gagel, et al.. (2010). Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. Journal of Clinical Oncology. 28(5). 767–772. 380 indexed citations

10.

Gralow, Julie R., J. Sybil Biermann, Azeez Farooki, et al.. (2007). NCCN task force report. Journal of the National Comprehensive Cancer Network. 9. 32 indexed citations

11.

Yeung, Sai‐Ching J. & Robert F. Gagel. (2003). Endocrine Paraneoplastic Syndromes (“Ectopic” Hormone Production). Journal of Substance Abuse. 8(4). 431–43. 5 indexed citations

12.

Newman, Connie B., Шломо Мелмед, Ajax E. George, et al.. (1998). Octreotide as Primary Therapy for Acromegaly¹. The Journal of Clinical Endocrinology & Metabolism. 83(9). 3034–3040. 14 indexed citations

13.

Thomas, Pamela M., Nelson Wohllk, Elbert S. Huang, et al.. (1996). Inactivation of the first nucleotide-binding fold of the sulfonylurea receptor, and familial persistent hyperinsulinemic hypoglycemia of infancy.. PubMed Central. 59(3). 510–8. 63 indexed citations

14.

Lou, Hua Jane, Robert F. Gagel, & Susan M. Berget. (1996). An intron enhancer recognized by splicing factors activates polyadenylation.. Genes & Development. 10(2). 208–219. 128 indexed citations

15.

Gagel, Robert F.. (1994). Multiple endocrine neoplasia: Preface. Endocrinology and Metabolism Clinics of North America. 23(1). 2 indexed citations

16.

Cote, Gilbert J., et al.. (1990). Calcitonin Exon Sequences Influence Alternative RNA Processing. Molecular Endocrinology. 4(11). 1744–1749. 20 indexed citations

17.

Rogers, Douglas G., et al.. (1989). 1,25-Dihydroxyvitamin D₃Silences 3′,5′-Cyclic Adenosine Monophosphate Enhancement of Somatostatin Gene Transcription in Human Thyroid C Cells. Molecular Endocrinology. 3(3). 547–551. 6 indexed citations

18.

Gagel, Robert F., Charles E. Jackson, Bruce A.J. Ponder, et al.. (1989). Multiple Endocrine Neoplasia Type 2 Syndromes: Nomenclature Recommendations from the Workshop Organizing Committee. 37(3). 99. 4 indexed citations

19.

Gagel, Robert F., Charles E. Jackson, Melvin A. Block, et al.. (1982). Age-related probability of development of hereditary medullary thyroid carcinoma. The Journal of Pediatrics. 101(6). 941–946. 52 indexed citations

20.

Wolfe, Hubert J., et al.. (1975). Adrenal medullary hyperplasia in familial medullary thyroid carcinoma. American Journal Of Pathology. 78(1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact